Stronger Together: Neurolex develops a “vocal biomarker” to rapidly screen for COVID-19

CEO Jim Schwoebel founded Neurolex after his brother experienced a psychotic episode, and he noticed that his brother’s voice changed. The Boston-based company has developed “vocal biomarkers” to detect mental health issues, and with the advent of the coronavirus pandemic is working to adapt the technology to identify COVID-19 symptoms using only a voice recording.

In this interview, hear the story behind vocal biomarkers, and how Neurolex has scaled to meet 10x demand under stringent security and compliance requirements during the COVID-19 pandemic.

If you’d like to conduct your own voice survey, take a look at SurveyLex, the Neurolex product that is being used to collect data for the vocal biomarkers.

This interview is part of the Stronger Together series. Click here for more interviews and additional resources for startups.